Synthesis,reactivity, in vitro boron neutron capture therapy assay,and molecular docking of fluorocyclocarboxyboranylamine

The one-pot reaction of Me₃NBH₂CN with Et₃O⁺BF₄⁻ followed by addition of BF₃·Et₂O and water produces a trimethylamine derivative of fluorocyclocarboxyboranylamine, Me₃NBH₂C(O₂BF₂NH₂) ( 1 ) in 36.0% yield. Compound 1 undergoes exchange reaction between the exo-Me₃N moiety and piperidine or pyridine to produce the corresponding piperidine-substituted fluorocyclocarboxyboranylamine ( 2 ) or pyridine-substituted fluorocyclocarboxyboranylamine ( 3 ) in 51.2% or 42.4% yields, respectively. The new compounds were characterized by ¹H, ¹³C, ¹¹B, and ¹⁹F nuclear magnetic resonance spectroscopy; Fourier-transform infrared spectroscopy; and elemental analyses and the crystal structure of 1 was determined to confirm its molecular geometry. The in vitro killing effects of 1 , along with its toxicity measurements and molecular docking interactions with matrix metalloproteinases showed a potential promise of such species as both boron neutron capture therapy and boron neutron capture synovectomy agents in the treatment of tumors and rheumatoid arthritis, respectively, in the presence of slow neutrons.